DE60034594D1 - Diagnose von malignen neoplasmen - Google Patents
Diagnose von malignen neoplasmenInfo
- Publication number
- DE60034594D1 DE60034594D1 DE60034594T DE60034594T DE60034594D1 DE 60034594 D1 DE60034594 D1 DE 60034594D1 DE 60034594 T DE60034594 T DE 60034594T DE 60034594 T DE60034594 T DE 60034594T DE 60034594 D1 DE60034594 D1 DE 60034594D1
- Authority
- DE
- Germany
- Prior art keywords
- haah
- neoplasms
- malignes
- diagnosis
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/11—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors (1.14.11)
- C12Y114/11016—Peptide-aspartate beta-dioxygenase (1.14.11.16), i.e. aspartyl (asparaginyl) beta-hydroxylase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US436184 | 1999-11-08 | ||
US09/436,184 US20030031670A1 (en) | 1999-11-08 | 1999-11-08 | Diagnosis and treatment of malignant neoplasms |
PCT/US2000/030738 WO2001035102A2 (en) | 1999-11-08 | 2000-11-08 | Diagnosis and treatment of malignant neoplasms |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60034594D1 true DE60034594D1 (de) | 2007-06-06 |
DE60034594T2 DE60034594T2 (de) | 2008-04-03 |
Family
ID=23731454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60034594T Expired - Lifetime DE60034594T2 (de) | 1999-11-08 | 2000-11-08 | Diagnose von malignen neoplasmen |
Country Status (9)
Country | Link |
---|---|
US (9) | US20030031670A1 (de) |
EP (2) | EP1881327A3 (de) |
JP (2) | JP4375932B2 (de) |
AT (1) | ATE360821T1 (de) |
AU (1) | AU783327B2 (de) |
CA (1) | CA2390374A1 (de) |
DE (1) | DE60034594T2 (de) |
ES (1) | ES2286041T3 (de) |
WO (1) | WO2001035102A2 (de) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002303802B8 (en) * | 1999-11-08 | 2008-12-18 | Panacea Pharmaceuticals, Inc | Diagnosis and treatment of malignant neoplasms |
US20050123545A1 (en) * | 1999-11-08 | 2005-06-09 | Wands Jack R. | Diagnosis and treatment of malignant neoplasms |
US20030031670A1 (en) * | 1999-11-08 | 2003-02-13 | Jack R. Wands | Diagnosis and treatment of malignant neoplasms |
US6835370B2 (en) * | 1999-11-08 | 2004-12-28 | Rhode Island Hospital | Diagnosis and treatment of malignant neoplasms |
CA2487143A1 (en) * | 2002-05-27 | 2003-12-04 | Bayer Healthcare Ag | Regulation of novel human asparagine-hydroxylases |
US20030013145A1 (en) * | 2002-08-12 | 2003-01-16 | Ted Titmas | Personal breast cancer indicator |
WO2005003302A2 (en) * | 2003-06-17 | 2005-01-13 | Medimmune, Inc. | Novel methods to modulate mast cells |
US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
WO2005016281A2 (en) * | 2003-08-13 | 2005-02-24 | Rhode Island Hospital | Diagnosis and treatment of malignant neoplasms |
WO2005037999A2 (en) * | 2003-10-14 | 2005-04-28 | Biogen Idec Ma Inc. | Treatment of cancer using antibodies to lrrc15 |
WO2005049802A2 (en) * | 2003-11-14 | 2005-06-02 | Massachusetts Institute Of Technology | Anti-hydroxylase antibodies and uses thereof |
WO2006044290A2 (en) | 2004-10-12 | 2006-04-27 | Board Of Trustees Of Michigan State University | Biosynthesis of philoroglucinol and preparation of 1,3-dihydroxybenzene therefrom |
WO2006128195A2 (en) * | 2005-05-27 | 2006-11-30 | Dana-Farber Cancer Institute | Methods of diagnosing and treating cancer by detection of chromosomal abnormalities |
US20080124718A1 (en) * | 2006-01-27 | 2008-05-29 | Panacea Pharmaceuticals, Inc. | Methods of diagnosing, predicting therapeutic efficacy and screening for new therapeutic agents for leukemia |
US7919092B2 (en) | 2006-06-13 | 2011-04-05 | Oncomed Pharmaceuticals, Inc. | Antibodies to notch receptors |
EP2125887A4 (de) | 2007-01-24 | 2010-11-10 | Oncomed Pharm Inc | Zusammensetzungen und verfahren zur behandlung und diagnostizierung von krebs |
US20090208491A1 (en) * | 2007-02-14 | 2009-08-20 | Austin Gurney | Compositions and Methods for Diagnosing and Treating Cancer |
US8257932B2 (en) * | 2007-02-21 | 2012-09-04 | The Regents Of The University Of California | Interfacing nanostructures to biological cells |
US20090298097A1 (en) * | 2007-07-17 | 2009-12-03 | Harris Pamela J | Methods for the diagnosis of lung cancer |
CA2715080C (en) | 2007-09-28 | 2021-09-28 | Intrexon Corporation | Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof |
US9132189B2 (en) | 2008-07-08 | 2015-09-15 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
JP5560270B2 (ja) | 2008-07-08 | 2014-07-23 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Notch結合剤およびアンタゴニストならびにその使用方法 |
PL3903829T3 (pl) | 2009-02-13 | 2023-08-14 | Immunomedics, Inc. | Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo |
EP2456458B1 (de) | 2009-07-24 | 2018-12-26 | Rhode Island Hospital | Impfstoffe aus dendritischen zellen für asparaginyl - beta - hydroxylase-exprimierende tumoren |
EP2478110B1 (de) | 2009-09-16 | 2016-01-06 | Immunomedics, Inc. | Klasse-i-anti-cea-antikörper und verwendungen davon |
WO2011068845A1 (en) | 2009-12-02 | 2011-06-09 | Immunomedics, Inc. | Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy |
EP2523682B1 (de) | 2010-01-13 | 2015-12-16 | Oncomed Pharmaceuticals, Inc. | Notch1-bindende wirkstoffe und verfahren zu deren verwendung |
WO2012003461A2 (en) | 2010-07-02 | 2012-01-05 | Draths Corporation | Phloroglucinol synthases and methods of making and using the same |
WO2012006245A1 (en) | 2010-07-06 | 2012-01-12 | Draths Corporation | Phloroglucinol reductase and methods of making and using the same |
WO2012006244A1 (en) | 2010-07-06 | 2012-01-12 | Draths Corporation | Method for producing phloroglucinol and dihydrophloroglucinol |
CA2831572C (en) | 2011-05-02 | 2019-11-26 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
US9316645B2 (en) | 2011-10-07 | 2016-04-19 | Brown University | Methods, compositions and kits for imaging cells and tissues using nanoparticles and spatial frequency heterodyne imaging |
EP2885002A4 (de) | 2012-08-14 | 2016-04-20 | Ibc Pharmaceuticals Inc | Umleitung t-zell-bispezifischer antikörper zur behandlung von krankheiten |
CN110818660B (zh) | 2012-09-21 | 2023-09-12 | 罗得岛医院 | 用于治疗癌症的β-羟化酶抑制剂 |
WO2017004144A1 (en) | 2015-07-01 | 2017-01-05 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
AU2013360335B2 (en) | 2012-12-13 | 2017-12-07 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
US20140356930A1 (en) * | 2013-06-03 | 2014-12-04 | Panacea Pharmaceuticals | Immune system enhancing immunotherapy for the treatment of cancer |
WO2015126548A1 (en) | 2014-02-21 | 2015-08-27 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to trop-2 expressing cells |
CN106029098A (zh) | 2014-02-25 | 2016-10-12 | 免疫医疗公司 | 人源化rfb4抗cd22抗体 |
WO2015164826A2 (en) | 2014-04-24 | 2015-10-29 | Rhode Island Hospital | ASPARTATE-β-HYDROXYLASE INDUCES EPITOPE-SPECIFIC T CELL RESPONSES IN TUMORS |
WO2015200260A1 (en) | 2014-06-24 | 2015-12-30 | Immunomedics, Inc. | Anti-histone therapy for vascular necrosis in severe glomerulonephritis |
EP3954373A1 (de) | 2014-10-07 | 2022-02-16 | Immunomedics, Inc. | Neoadjuvante verwendung von antikörper-wirkstoff-konjugaten |
CN107428837A (zh) | 2015-04-22 | 2017-12-01 | 免疫医疗公司 | 循环trop‑2阳性癌细胞的分离、检测、诊断和/或鉴定 |
EP3313443B9 (de) | 2015-06-25 | 2023-10-04 | Immunomedics, Inc. | Kombination von anti-hla-dr- oder anti-trop-2-antikörpern mit mikrotubuli-inhibitoren, parp-inhibitoren, bruton-kinase-inhibitoren oder phosphoinositol-3-kinase-inhibitoren zur signifikanten verbesserung des therapeutischen ergebnisses bei krebs |
AU2016315932B2 (en) | 2015-09-01 | 2020-04-09 | 8 Rivers Capital, Llc | Systems and methods for power production using nested CO2 cycles |
JPWO2022239720A1 (de) | 2021-05-10 | 2022-11-17 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK175432B1 (da) * | 1984-10-30 | 2004-10-18 | Otsuka Pharma Co Ltd | Middel til forögelse af anticancervirkningen af anticancerforbindelser |
US4735210A (en) * | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US5776093A (en) * | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
WO1989006692A1 (en) * | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
US5939531A (en) * | 1991-07-15 | 1999-08-17 | Novartis Corp. | Recombinant antibodies specific for a growth factor receptor |
US5660827A (en) * | 1992-03-05 | 1997-08-26 | Board Of Regents, The University Of Texas System | Antibodies that bind to endoglin |
US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
US6046219A (en) * | 1995-01-20 | 2000-04-04 | Cornell Research Foundation, Inc. | Method for the treatment of conditions mediated by collagen formation together with cell proliferation by application of inhibitors of protein hydroxylation |
US5789426A (en) * | 1995-01-20 | 1998-08-04 | Cornell Research Foundation, Inc. | Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation |
US5830478A (en) * | 1995-06-07 | 1998-11-03 | Boston Biomedical Research Institute | Method for delivering functional domains of diphtheria toxin to a cellular target |
US5854205A (en) * | 1995-10-23 | 1998-12-29 | The Children's Medical Center Corporation | Therapeutic antiangiogenic compositions and methods |
US5814500A (en) * | 1996-10-31 | 1998-09-29 | The Johns Hopkins University School Of Medicine | Delivery construct for antisense nucleic acids and methods of use |
WO1998019691A1 (en) * | 1996-11-04 | 1998-05-14 | The General Hospital Corporation | Dominant negative mutants of irs-1 and uses thereof |
AUPO727097A0 (en) * | 1997-06-10 | 1997-07-03 | Unisearch Limited | Method of treatment of hepatoma and pharmaceutical compositions for use therein |
JP2002514925A (ja) * | 1997-07-01 | 2002-05-21 | ヒューマン ジノーム サイエンシーズ,インコーポレイテッド | 19個のヒト分泌タンパク質 |
US6166176A (en) | 1998-03-17 | 2000-12-26 | Immvarx, Inc. | Cancer marker protein and peptides thereof |
US20030031670A1 (en) * | 1999-11-08 | 2003-02-13 | Jack R. Wands | Diagnosis and treatment of malignant neoplasms |
US6835370B2 (en) * | 1999-11-08 | 2004-12-28 | Rhode Island Hospital | Diagnosis and treatment of malignant neoplasms |
US20050123545A1 (en) * | 1999-11-08 | 2005-06-09 | Wands Jack R. | Diagnosis and treatment of malignant neoplasms |
WO2004072081A1 (en) * | 2003-02-10 | 2004-08-26 | Cellular Genomics, Inc. | Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity |
-
1999
- 1999-11-08 US US09/436,184 patent/US20030031670A1/en not_active Abandoned
-
2000
- 2000-11-08 EP EP07008309A patent/EP1881327A3/de not_active Withdrawn
- 2000-11-08 EP EP00978436A patent/EP1259813B1/de not_active Expired - Lifetime
- 2000-11-08 AT AT00978436T patent/ATE360821T1/de not_active IP Right Cessation
- 2000-11-08 AU AU15901/01A patent/AU783327B2/en not_active Ceased
- 2000-11-08 WO PCT/US2000/030738 patent/WO2001035102A2/en active IP Right Grant
- 2000-11-08 CA CA002390374A patent/CA2390374A1/en not_active Abandoned
- 2000-11-08 DE DE60034594T patent/DE60034594T2/de not_active Expired - Lifetime
- 2000-11-08 ES ES00978436T patent/ES2286041T3/es not_active Expired - Lifetime
- 2000-11-08 JP JP2001536582A patent/JP4375932B2/ja not_active Expired - Fee Related
-
2001
- 2001-07-11 US US09/903,248 patent/US6783758B2/en not_active Expired - Lifetime
- 2001-07-11 US US09/903,199 patent/US6797696B2/en not_active Expired - Lifetime
- 2001-07-11 US US09/903,063 patent/US6815415B2/en not_active Expired - Lifetime
- 2001-07-11 US US09/903,216 patent/US6812206B2/en not_active Expired - Lifetime
- 2001-07-11 US US09/903,023 patent/US7094556B2/en not_active Expired - Fee Related
-
2006
- 2006-03-15 US US11/376,941 patent/US20060211058A1/en not_active Abandoned
-
2008
- 2008-05-21 JP JP2008132974A patent/JP2008292486A/ja active Pending
-
2009
- 2009-11-25 US US12/625,871 patent/US20100144837A1/en not_active Abandoned
- 2009-11-25 US US12/625,729 patent/US20100136581A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1881327A2 (de) | 2008-01-23 |
AU1590101A (en) | 2001-06-06 |
EP1259813A2 (de) | 2002-11-27 |
US7094556B2 (en) | 2006-08-22 |
US6797696B2 (en) | 2004-09-28 |
US20020122802A1 (en) | 2002-09-05 |
US20100136581A1 (en) | 2010-06-03 |
US20060211058A1 (en) | 2006-09-21 |
WO2001035102A2 (en) | 2001-05-17 |
ATE360821T1 (de) | 2007-05-15 |
US20020102263A1 (en) | 2002-08-01 |
US20020146421A1 (en) | 2002-10-10 |
JP2008292486A (ja) | 2008-12-04 |
JP2003519365A (ja) | 2003-06-17 |
ES2286041T3 (es) | 2007-12-01 |
US20030031670A1 (en) | 2003-02-13 |
DE60034594T2 (de) | 2008-04-03 |
EP1259813B1 (de) | 2007-04-25 |
WO2001035102A3 (en) | 2002-09-12 |
EP1881327A3 (de) | 2008-04-02 |
US6783758B2 (en) | 2004-08-31 |
US20020114811A1 (en) | 2002-08-22 |
CA2390374A1 (en) | 2001-05-17 |
JP4375932B2 (ja) | 2009-12-02 |
US20100144837A1 (en) | 2010-06-10 |
US6815415B2 (en) | 2004-11-09 |
US6812206B2 (en) | 2004-11-02 |
AU783327B2 (en) | 2005-10-13 |
US20020114810A1 (en) | 2002-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60034594D1 (de) | Diagnose von malignen neoplasmen | |
DE60237624D1 (de) | Diagnose und behandlung von malignen neoplasmen | |
ATE364089T1 (de) | Reagenzien und methoden zum nachweis von erkrankungen der brust | |
ATE230487T1 (de) | Verfahren zur frühen diagnose von carcinomen | |
ATE376187T1 (de) | Nachweis von erkrankungen der nieren und behandlung | |
WO2001075177A3 (en) | Tumor markers in ovarian cancer | |
ATE437369T1 (de) | Enzymkatalysierte metalldeposition zum verstärkten in-situ-nachweis von immunhistologischen epitopen und nukleinsäuresequenzen | |
DK1064303T3 (da) | Monoklonale antistoffer, der er specifikke for det prostataspecifikke membranantigens ekstracellulære domæne | |
JP2015533788A5 (de) | ||
WO1998037418A3 (en) | Compounds for immunodiagnosis of prostate cancer and methods for their use | |
DK0991421T3 (da) | Påvisning og modulering af IAP'er og NAIP i forbindelse med diagnose og behandling af proliferativ sygdom | |
CA2280930A1 (en) | Protein markers for lung cancer and use thereof | |
ATE302278T1 (de) | Diagnose und behandlung von aur1 und/oder aur2 verwandten erkrankungen | |
CN105566499B (zh) | 一种多聚体酶‑抗体及其制备方法 | |
DE69839123D1 (de) | Prostattumor polynukleotid- und antigenzusammensetzungen | |
DE69735436D1 (de) | Methode zum nachweis von zell-apoptose | |
CN102687011A (zh) | 癌症生物标志物及其应用 | |
DK1075277T3 (da) | Fremgangsmåder til detektion og inhibering af angiogenese | |
DE60044350D1 (de) | Prostata-spezifisches gen pcgem1 und methoden zu dessen verwendung zur erkennung, behandlung und prävention von prostatakrebs | |
DE69803279D1 (de) | Schnelle krebs-diagnose | |
Sandusky et al. | Immunocytochemical study of tissues from clinically normal dogs and of neoplasms, using keratin monoclonal antibodies | |
RU2011104704A (ru) | Средство для индукции иммунитета и способ выявления злокачественной опухоли | |
ES2191173T3 (es) | Anticuerpos monoclonales contra un complejo de act humana y una proteasa de serina. | |
ATE532796T1 (de) | Immunassays zur spezifischen bestimmung von scca- isoformen | |
WO2005016281A3 (en) | Diagnosis and treatment of malignant neoplasms |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |